IL274071B2 - Method for in vivo generation of multispecific antibodies from monospecific antibodies - Google Patents
Method for in vivo generation of multispecific antibodies from monospecific antibodiesInfo
- Publication number
- IL274071B2 IL274071B2 IL274071A IL27407120A IL274071B2 IL 274071 B2 IL274071 B2 IL 274071B2 IL 274071 A IL274071 A IL 274071A IL 27407120 A IL27407120 A IL 27407120A IL 274071 B2 IL274071 B2 IL 274071B2
- Authority
- IL
- Israel
- Prior art keywords
- domain
- variable domain
- antibody
- polypeptide
- chain variable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Claims (14)
1. 274071/ - 239 - Claims 1. A composition comprising a) a first multimeric polypeptide comprising a first polypeptide comprising i) in N- to C-terminal direction a) a first antibody variable domain selected from a pair of an antibody light and heavy chain variable domain specifically binding to a first target, and b) a first human immunoglobulin G CH3 domain, ii) a pair of an antibody light and heavy chain variable domain specifically binding to a cell surface antigen either N-terminal to the first antibody variable domain or C-terminal to the first CH3 domain, a second polypeptide comprising i) in N- to C-terminal direction a) a second antibody variable domain selected from a pair of an antibody light and heavy chain variable domain specifically binding to a third target, and b) a second human immunoglobulin G CH3 domain, wherein the second antibody variable domain is an antibody light chain variable domain if the first antibody variable domain is an antibody heavy chain variable domain; or the second antibody variable domain is an antibody heavy chain variable domain if the first antibody variable domain is an antibody light chain variable domain; and wherein the second CH3 domain comprises a perturbing mutation D356K or E357K, whereby all numbering is according to Kabat EU index, whereby the first CH3 domain comprises a) the amino acid residue K at position 439 if the perturbing mutations is D356K, or b) the amino acid residue K at position 370 if the perturbing mutations is E357K; and b) a second multimeric polypeptide comprising a first polypeptide comprising i) in N- to C-terminal direction a) a first antibody variable domain selected from a pair of an antibody light and heavy chain variable 274071/ - 240 - domain specifically binding to a first target, and b) a first human immunoglobulin G CH3 domain, ii) a pair of an antibody light and heavy chain variable domain specifically binding to a cell surface antigen either N-terminal to the first antibody variable domain or C-terminal to the first CH3 domain, a second polypeptide comprising i) in N- to C-terminal direction a) a second antibody variable domain selected from a pair of an antibody light and heavy chain variable domain specifically binding to a third target, and b) a second human immunoglobulin G CH3 domain, wherein the second antibody variable domain is an antibody light chain variable domain if the first antibody variable domain is an antibody heavy chain variable domain; or the second antibody variable domain is an antibody heavy chain variable domain if the first antibody variable domain is an antibody light chain variable domain; and wherein the second CH3 domain comprises a perturbing mutation K370E or K439E, whereby all numbering is according to Kabat EU index, whereby the first CH3 domain comprises a) the amino acid residue E at position 357 if the perturbing mutations is K370E, or b) the amino acid residue D at position 356 if the perturbing mutations is K439E; wherein the first multimeric polypeptide and the second multimeric polypeptide are characterized in that - the second CH3 domain of the first multimeric polypeptide comprises the mutation D356K and the second CH3 domain of the second multimeric polypeptide comprises the mutation K439E, or the second CH3 domain of the first multimeric polypeptide comprises the mutation E357K and the second CH3 domain of the second multimeric polypeptide comprises the mutation K370E; and - the first antibody variable domain of the first multimeric polypeptide and the first variable domain of the second multimeric polypeptide are a pair of 274071/ - 241 - an antibody light chain variable domain and an antibody heavy chain variable domain that specifically bind to the first target, and the second antibody variable domain of the first multimeric polypeptide and the second variable domain of the second multimeric polypeptide are a pair of an antibody light chain variable domain and an antibody heavy chain variable domain that specifically bind to the third target.
2. The composition according to claim 1, wherein within the first multimeric polypeptide and the second multimeric polypeptide the first CH3 domain and the second CH3 domain comprise further mutations to foster heterodimer formation between said first CH3 domain and said second CH3 domain and that are different from the perturbing mutation.
3. The composition according to claim 1 or 2, wherein the first CH3 domain of the first multimeric polypeptide and the second CH3 domain of the second multimeric polypeptide comprise the same mutations to foster heterodimer formation; and wherein the second CH3 domain of the first multimeric polypeptide and the first CH3 domain of the second multimeric polypeptide comprise the same mutations to foster heterodimer formation.
4. The composition according to any one of claims 1 to 3, wherein the first CH3 domain of the first polypeptide comprises a) the mutation T366W, or b) the mutations T366S/L368A/Y407V, and the second CH3 domain of the first polypeptide comprises a) the mutations T366S/L368A/Y407V if the first CHdomain comprises the mutation T366W, or b) the mutation T366W if the first CH3 domain comprises the mutations T366S/L368A/Y407V.
5. The composition according to any one of claims 1 to 4, wherein the first polypeptide and the second polypeptide are a non-covalent dimer.
6. The composition according to any one of claims 1 to 5, wherein the first variable domain and the second variable domain form a non-functional binding site. 274071/ - 242 -
7. The composition according to any one of claims 1 to 6, wherein the first and the second polypeptide each comprise the amino acid sequence DKTHTSPPS (SEQ ID NO: 66) or DKTHT (SEQ ID NO: 94) or GGGS (SEQ ID NO: 69) or DKTHGGGGS (SEQ ID NO: 97) N-terminal to each of the first and second variable domains.
8. The composition according to any one of claims 1 to 7, wherein the first, second and third target are different.
9. The composition according to any one of claims 1 to 8, wherein each of the first and the second polypeptide further comprises an immunoglobulin G CHdomain directly N-terminal to the CH3 domain.
10. The composition according to any one of claims 1 to 9, wherein the first and/or the third target is human CD3.
11. The composition according to any one of claims 1 to 10, wherein the second polypeptide of the first multimeric polypeptide and/or the second polypeptide of the second multimeric polypeptide comprises a pair of an antibody light and heavy chain variable domain specifically binding to a cell surface antigen either N-terminal to the second antibody variable domain or C-terminal to the second CH3 domain.
12. The composition according to any one of claims 1 to 11, wherein the human immunoglobulin G is human IgG1 or human IgG2 or IgG3 or human IgG4.
13. The composition according to any one of claims 1 to 12, wherein the composition is a pharmaceutical composition and optionally further comprises a pharmaceutically acceptable excipient.
14. The composition according to any one of claims 1 to 13 for use as a medicament. For the Applicants, REINHOLD COHN AND PARTNERS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17199086 | 2017-10-30 | ||
| PCT/EP2018/079523 WO2019086362A1 (en) | 2017-10-30 | 2018-10-29 | Method for in vivo generation of multispecific antibodies from monospecific antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL274071A IL274071A (en) | 2020-06-30 |
| IL274071B1 IL274071B1 (en) | 2025-06-01 |
| IL274071B2 true IL274071B2 (en) | 2025-10-01 |
Family
ID=60413028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL274071A IL274071B2 (en) | 2017-10-30 | 2018-10-29 | Method for in vivo generation of multispecific antibodies from monospecific antibodies |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12180279B2 (en) |
| EP (1) | EP3704145A1 (en) |
| JP (2) | JP7438942B2 (en) |
| KR (1) | KR102831164B1 (en) |
| CN (1) | CN111372947B (en) |
| AU (1) | AU2018358883B2 (en) |
| BR (1) | BR112020007736A2 (en) |
| CA (1) | CA3078676A1 (en) |
| IL (1) | IL274071B2 (en) |
| MX (1) | MX2020004100A (en) |
| TW (1) | TWI832824B (en) |
| WO (1) | WO2019086362A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL274071B2 (en) * | 2017-10-30 | 2025-10-01 | Hoffmann La Roche | Method for in vivo generation of multispecific antibodies from monospecific antibodies |
| CN110507824A (en) * | 2018-05-21 | 2019-11-29 | 荣昌生物制药(烟台)有限公司 | A kind of Anti-mesothelin antibodies and its antibody drug conjugate |
| JP7812230B2 (en) * | 2019-04-25 | 2026-02-09 | エフ. ホフマン-ラ ロシュ アーゲー | Generation of antibody-derived polypeptides by polypeptide chain exchange |
| EP3959237A1 (en) * | 2019-04-25 | 2022-03-02 | F. Hoffmann-La Roche AG | Therapeutic multispecific polypeptides activated by polypeptide chain exchange |
| CN114585651A (en) * | 2019-08-08 | 2022-06-03 | 再生元制药公司 | Novel antigen binding molecular forms |
| WO2021246720A1 (en) * | 2020-06-01 | 2021-12-09 | 머스트바이오 주식회사 | Bispecific antibody or antigen-binding fragment thereof, and preparation method therefor |
| MX2023006899A (en) * | 2020-12-10 | 2023-09-04 | Invenra Inc | Orthogonal mutations for heterodimerization. |
| WO2022129313A1 (en) | 2020-12-18 | 2022-06-23 | F. Hoffmann-La Roche Ag | Precursor proteins and kit for targeted therapy |
| AU2022318255A1 (en) * | 2021-07-27 | 2024-01-18 | Morphosys Ag | Combinations of antigen binding molecules |
| CN120187748A (en) * | 2022-11-15 | 2025-06-20 | 豪夫迈·罗氏有限公司 | Antigen Binding Molecules |
| CN120603846A (en) * | 2023-01-25 | 2025-09-05 | 豪夫迈·罗氏有限公司 | Multispecific antibodies carrying payloads |
| EP4574839A1 (en) * | 2023-12-22 | 2025-06-25 | BioNTech SE | Co-delivery system |
| AU2024376185A1 (en) | 2023-11-10 | 2026-05-14 | BioNTech SE | Co-delivery system |
| CN117467025B (en) * | 2023-12-28 | 2024-04-16 | 上海鼎新基因科技有限公司 | A dual-function fusion protein of anti-VEGF and complement and its application |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (en) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | Modifications of or for denatured antibodies |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| FI903489A7 (en) | 1988-11-11 | 1990-07-10 | Medical Res Council | Ligands containing one moiety, receptors containing these ligands, methods for their preparation and uses of the ligands and receptors |
| DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| FI941572L (en) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Combination and method of use of anti-erbB-2 monoclonal antibodies |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| AU677216B2 (en) | 1992-07-27 | 1997-04-17 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Targeting of liposomes to the blood-brain barrier |
| GB9221657D0 (en) | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant bispecific antibodies |
| ATE139900T1 (en) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES AGAINST HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR THE TREATMENT OF B CELL LYMPHOMA |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| DE59610754D1 (en) | 1996-07-25 | 2003-11-06 | Gsf Forschungszentrum Umwelt | SIMPLIFIED MANUFACTURE OF SPECIFIC ANTIBODY FRAGMENTS |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| KR100797667B1 (en) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | How to regulate transcription of foreign genes |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| AU767394C (en) | 1999-12-29 | 2005-04-21 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| PT2857516T (en) | 2000-04-11 | 2017-08-28 | Genentech Inc | Multivalent antibodies and uses therefor |
| DE10121982B4 (en) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanoparticles of protein with coupled apolipoprotein E to overcome the blood-brain barrier and process for their preparation |
| AU2003266502A1 (en) | 2002-08-16 | 2004-03-03 | The University Of Tokyo | Method of assaying interaction between proteins |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| JP4995423B2 (en) | 2002-12-03 | 2012-08-08 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | Artificial low density lipoprotein carrier for transporting substances across the blood-brain barrier |
| HUE035898T2 (en) | 2002-12-16 | 2018-05-28 | Genentech Inc | Immunoglobulin variants and uses thereof |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7700097B2 (en) | 2003-06-27 | 2010-04-20 | Biogen Idec Ma Inc. | Purification and preferential synthesis of binding molecules |
| US8076459B2 (en) | 2003-10-16 | 2011-12-13 | Micromet Ag | Multispecfic deimmunized CD3-binders |
| EP1693386A4 (en) | 2003-11-04 | 2008-12-31 | Chugai Pharmaceutical Co Ltd | METHOD FOR PRODUCING ANTIBODIES |
| ES2605443T3 (en) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| WO2005062916A2 (en) | 2003-12-22 | 2005-07-14 | Centocor, Inc. | Methods for generating multimeric molecules |
| WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
| EP1805320B1 (en) | 2004-10-22 | 2014-09-03 | Amgen Inc. | Methods for refolding of recombinant antibodies |
| KR101374454B1 (en) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | Methods for producing polypeptides by regulating polypeptide association |
| EP1962961B1 (en) | 2005-11-29 | 2013-01-09 | The University Of Sydney | Demibodies: dimerisation-activated therapeutic agents |
| DK1999154T3 (en) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | MANUFACTURED HETERODIMERED PROTEIN DOMAINS |
| JP5144499B2 (en) | 2006-03-31 | 2013-02-13 | 中外製薬株式会社 | Antibody modification method for purifying bispecific antibodies |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
| EP2626372B1 (en) | 2007-03-29 | 2018-03-21 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| ES2687808T3 (en) | 2007-09-26 | 2018-10-29 | Chugai Seiyaku Kabushiki Kaisha | Constant region of modified antibody |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| EP3663318A1 (en) * | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| TWI507525B (en) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | Easy-to-separate bispecific antibody with native immunoglobulin form |
| US20130089554A1 (en) | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| PT2560993T (en) | 2010-04-20 | 2024-09-16 | Genmab As | FC HETERODIMERIC ANTIBODY CONTAINING PROTEINS AND METHODS FOR THEIR PRODUCTION |
| WO2011133886A2 (en) | 2010-04-23 | 2011-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| CN103068846B9 (en) * | 2010-08-24 | 2016-09-28 | 弗·哈夫曼-拉罗切有限公司 | Bispecific antibodies comprising disulfide-stabilized Fv fragments |
| CN103429620B (en) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | Antibody design for stable heterodimerization with mutations in the Fc domain |
| KR101721301B1 (en) | 2011-08-23 | 2017-03-29 | 로슈 글리카트 아게 | Bispecific antigen binding molecules |
| IN2014CN03887A (en) | 2011-10-27 | 2015-10-16 | Genmab As | |
| US9527927B2 (en) | 2011-12-20 | 2016-12-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| WO2013157953A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
| UY35148A (en) | 2012-11-21 | 2014-05-30 | Amgen Inc | HETERODIMERIC IMMUNOGLOBULINS |
| CA2925256C (en) | 2013-09-27 | 2023-08-15 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
| HUE050159T2 (en) | 2013-12-17 | 2020-11-30 | Genentech Inc | Anti-CD3 antibodies and methods of administration |
| US20170211876A1 (en) | 2014-06-12 | 2017-07-27 | Hoffmann-La Roche Inc. | Method for selecting antibodies with modified fcrn interaction |
| PL3177643T3 (en) | 2014-08-04 | 2019-09-30 | F.Hoffmann-La Roche Ag | Bispecific t cell activating antigen binding molecules |
| WO2016087416A1 (en) | 2014-12-03 | 2016-06-09 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
| ES2935274T3 (en) | 2014-12-05 | 2023-03-03 | Merck Patent Gmbh | domain swapping antibody |
| KR101851380B1 (en) | 2015-10-12 | 2018-04-23 | 아주대학교산학협력단 | Method to generate CH3 domain mutant pairs of heterodimeric Fc using yeast mating and CH3 domain mutant pairs thereby |
| JP6675017B2 (en) | 2016-05-02 | 2020-04-01 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Contrast body-single chain target binding substance |
| JP7556687B2 (en) | 2017-02-24 | 2024-09-26 | 中外製薬株式会社 | Pharmaceutical compositions, antigen-binding molecules, methods of treatment, and screening methods |
| WO2019077092A1 (en) * | 2017-10-20 | 2019-04-25 | F. Hoffmann-La Roche Ag | Method for generating multispecific antibodies from monospecific antibodies |
| IL274071B2 (en) * | 2017-10-30 | 2025-10-01 | Hoffmann La Roche | Method for in vivo generation of multispecific antibodies from monospecific antibodies |
-
2018
- 2018-10-29 IL IL274071A patent/IL274071B2/en unknown
- 2018-10-29 MX MX2020004100A patent/MX2020004100A/en unknown
- 2018-10-29 CN CN201880071568.9A patent/CN111372947B/en active Active
- 2018-10-29 EP EP18800530.0A patent/EP3704145A1/en active Pending
- 2018-10-29 WO PCT/EP2018/079523 patent/WO2019086362A1/en not_active Ceased
- 2018-10-29 CA CA3078676A patent/CA3078676A1/en active Pending
- 2018-10-29 AU AU2018358883A patent/AU2018358883B2/en active Active
- 2018-10-29 TW TW107138194A patent/TWI832824B/en active
- 2018-10-29 JP JP2020524170A patent/JP7438942B2/en active Active
- 2018-10-29 BR BR112020007736-4A patent/BR112020007736A2/en active Search and Examination
- 2018-10-29 KR KR1020207014733A patent/KR102831164B1/en active Active
-
2020
- 2020-04-28 US US16/860,406 patent/US12180279B2/en active Active
-
2023
- 2023-10-06 JP JP2023174208A patent/JP2024001197A/en active Pending
-
2024
- 2024-12-12 US US18/979,221 patent/US20250206821A1/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| KLAUS MAYER ET AL,, TRIFABS-TRIVALENT IGG-SHAPED BISPECIFIC ANTIBODY DERIVATIVES: DESIGN, GENERATION, CHARACTERIZATION AND APPLICATION FOR TARGETED PAYLOAD DELIVERY, 17 November 2015 (2015-11-17) * |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020007736A2 (en) | 2020-10-20 |
| CA3078676A1 (en) | 2019-05-09 |
| WO2019086362A1 (en) | 2019-05-09 |
| CN111372947A (en) | 2020-07-03 |
| TW201932494A (en) | 2019-08-16 |
| US20250206821A1 (en) | 2025-06-26 |
| TWI832824B (en) | 2024-02-21 |
| JP2024001197A (en) | 2024-01-09 |
| JP7438942B2 (en) | 2024-02-27 |
| IL274071B1 (en) | 2025-06-01 |
| JP2021501181A (en) | 2021-01-14 |
| KR102831164B1 (en) | 2025-07-07 |
| MX2020004100A (en) | 2020-07-24 |
| KR20200074195A (en) | 2020-06-24 |
| AU2018358883B2 (en) | 2025-09-25 |
| EP3704145A1 (en) | 2020-09-09 |
| US12180279B2 (en) | 2024-12-31 |
| CN111372947B (en) | 2025-08-15 |
| AU2018358883A1 (en) | 2020-04-23 |
| IL274071A (en) | 2020-06-30 |
| US20200255522A1 (en) | 2020-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274071B1 (en) | Method for generating in vivo multispecific antibodies from monospecific antibodies | |
| CN107922486B (en) | Heterodimeric Multispecific Antibody Format | |
| JP2018537966A5 (en) | ||
| HRP20241775T1 (en) | BISPECIFIC ANTIBODIES THAT SPECIFICALLY BIND TO PD1 AND LAG3 | |
| CA2963615C (en) | Domain-exchanged antibody | |
| FI3529269T3 (en) | Antibody constructs | |
| JP2020531438A5 (en) | Proteins that bind to NKG2D, CD16, and HLA-E | |
| JP2019534277A5 (en) | ||
| JP2017520575A5 (en) | ||
| RU2018142544A (en) | SPECIFIC BINDING PROTEINS AND WAYS OF THEIR APPLICATION | |
| HRP20220304T1 (en) | Anti-transferrin receptor antibodies with tailored affinity | |
| JP2021522162A5 (en) | ||
| FI3392276T3 (en) | Heterodimer molecule based on ch3 structural domain, and preparation method therefor and use thereof | |
| RU2019108429A (en) | MODIFIED ASYMMETRIC ANTIBODIES CONNECTING FC-RECEPTOR AND METHODS OF THEIR APPLICATION | |
| HRP20191766T1 (en) | Fc-region variants with modified fcrn-binding and methods of use | |
| RU2016133345A (en) | OPTIONS OF FC AREA WITH MODIFIED ABILITIES CONTACT FCRN | |
| JP2016508153A5 (en) | ||
| RU2015140915A (en) | BSPECIFIC ANTI-BINDING MOLECULES ACTIVATING T-CELLS | |
| JP2016188209A5 (en) | ||
| HRP20211357T1 (en) | Bispecific antibodies specific for pd1 and tim3 | |
| JP2018517431A5 (en) | ||
| WO2016191643A4 (en) | Tigit-binding agents and uses thereof | |
| RU2016151645A (en) | SPECIFIC HETERODIMERIC DIANTISTS AND THEIR APPLICATION | |
| JP2022504826A5 (en) | ||
| JP2020502233A5 (en) |